chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 41.0
Sex: F
Vaccine: TYP, YF
Symptoms: No adverse event, Product preparation error
Clinical narrative: Patient may have received a YF-VAX dose using a diluent from Merck that contains 0.7ml sterile water instead of the diluent supplied with the YF-VAX with no reported adverse event; Initial information received on 24-Mar-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 41 years old female patient who may have received a yf-vax dose using a diluent from  merck that contains 0.7ml sterile water instead of the diluent supplied with the yf-vax with no reported adverse event while receiving vaccine yellow fever vaccine -  [YF-Vax].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included typhoid vaccine polysacch VI (Typhim VI).  On 23-Mar-2022, the patient received a dose of suspect yellow fever vaccine - , Solution for injection (lot UJ409AA; expiry date: 22-Oct-2022; strength: unknown) (frequency: once) total at a dose of 0.5 ml via subcutaneous route in the left arm  for Immunization.  On 23-MAR-2022, the patient may have received a yellow fever vaccine -  dose using a diluent from  merck that contains 0.7ml sterile water instead of the diluent supplied with the yellow fever vaccine -  with no reported adverse event (product preparation issue) (latency: same day).  Action taken : not applicable.  At time of reporting, the outcome was Unknown for the event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 0.25
Sex: U
Vaccine: DTAPIPVHIB
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: administering the patient's 2-month dose of PENTACEL at 3 months of age, with no reported adverse event; Initial information received on 25-Mar-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 3 months old and unknown gender patient who experienced administering the patient's 2-month dose of pentacel at 3 months of age, with no reported adverse event while receiving vaccine Diphtheria/tetanus/5 hybrid ac pertussis/ipv(mrc5)/hib(prp/t) vaccine [pentacel].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included hib vaccine conj (tet tox) (acthib) for Immunisation.  On an unknown date, the patient received  suspect Diphtheria/tetanus/5 hybrid ac pertussis/ipv(mrc5)/hib(prp/t) vaccine Suspension for injection(strength,dose,lot number not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date the administering the patient's 2-month dose of pentacel at 3 months of age, with no reported adverse event (inappropriate schedule of product administration) (unknown latency) following the administration of Diphtheria/tetanus/5 hybrid ac pertussis/ipv(mrc5)/hib(prp/t) vaccine.  Action taken was not applicable.  At time of reporting, the outcome was Unknown for the event.     This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 41.0
Sex: U
Vaccine: DTAPIPVHIB
Symptoms: No adverse event, Wrong product administered
Clinical narrative: received a PENTACEL vaccination in the office on 25MAR2022 instead of Boostrix with no reported adverse event; off-label use as per local labelling due to the age of the patient with no reported adverse event; Initial information received on 25-Mar-2022 regarding an unsolicited valid  non-serious case received from a pharmacist via call center  This case involves a 41 years old and unknown gender patient who had received a pentacel vaccination in the office on 25mar2022 instead of boostrix with no reported adverse event and off-label use as per local labelling due to the age of the patient with no reported adverse event while receiving vaccine diphtheria/tetanus/5 hybrid ac pertussis/IPV(MRC5)/HIB(PRP/T) vaccine [Pentacel].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 25-Mar-2022, the patient received a  dose of suspect diphtheria/tetanus/5 hybrid ac pertussis/ipv(mrc5)/hib(prp/t) vaccine Suspension for injection (strength, site, dose, route, lot number, expiry date unknown) for immunisation  On 25-Mar-2022 the patient developed non-serious events received a pentacel vaccination in the office on 25-Mar-2022 instead of boostrix with no reported adverse event (wrong product administered) and off-label use as per local labelling due to the age of the patient with no reported adverse event (off label use) on the same day following the administration of diphtheria/tetanus/5 hybrid ac pertussis/IPV(MRC5)/HIB(PRP/T) vaccine.  Action taken was not applicable.   At time of reporting, the outcome was Unknown for both the events   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AE/PQC reported.; temperature excursion / the vaccines were administered after the excursion; This spontaneous report was received from an office manager and refers to a patient of unknown age and gender. The patient's concurrent conditions and medical history, allergies, drug reactions were not provided. The patient's concomitant therapies included sterile diluent.  On 02-NOV-2021, the patient was vaccinated with an improperly stored measles, mumps, rubella and varicella (oka-merck) virus vaccine live (recombinant Human albumin) (PROQUAD) in dose 0.5 ml, (lot # U017140, verified as valid with expiration date 28-NOV-2022, albumin status: rHa) (dose number, route of administration and anatomical location were not reported) for prophylaxis (product storage error). The temperature to which the vaccine was exposed was 6 Fahrenheit degrees up to 14 Fahrenheit degrees and the time frame was reported as 4 hours and 14 Fahrenheit degrees up to 46 Fahrenheit degrees for 4 hours and 45 minutes. No previous temperature excursions were reported. No additional adverse event was reported (No adverse event). It was unknown if a digital data logger was involved.  This is one of several cases received from the same reporter.; Sender's Comments:  US-009507513-2203USA001850: US-009507513-2203USA007379: US-009507513-2203USA001841: US-009507513-2203USA001716: US-009507513-2203USA001578: US-009507513-2203USA001612: US-009507513-2203USA001617: US-009507513-2203USA001688: US-009507513-2203USA001890:
Sex: U
Vaccine: RV5
Symptoms: Expired product administered
Clinical narrative: No additional information provided; an expired dose of ROTATEQ was administered to the patient; This spontaneous report was received from a registered nurse referring to a patient of unknown age and gender. The patient's concurrent conditions, medical history, drug reactions/allergies and concomitant therapies were not reported.  On 22-MAR-2022, the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) 2 mL, lot #1707460, expiration date: 14-MAR-2022 (strength, and route of administration were not provided) for prophylaxis (expired product administered). The administered vaccine had not been involved in any temperature excursions. No additional information provided.  This is one of three reports received from the same reporter.; Sender's Comments:  US-009507513-2203USA008707: US-009507513-2203USA008826:
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: pain down her right side from her hip down after getting the booster dose; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (pain down her right side from her hip down after getting the booster dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.   No Medical History information was reported.    In December 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (pain down her right side from her hip down after getting the booster dose). At the time of the report, ARTHRALGIA (pain down her right side from her hip down after getting the booster dose) outcome was unknown.            No concomitant medications was reported. No treatment information was reported. Patient was reporting adverse event for her mother. Patient took 2nd dose on 23 feb 2021 which was of other manufacturer.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Axillary Right: Multiple Lymph Node:  3.7 x 2.2 x2.4 cm /lymph node 4.2 x 2.1 x 2.2 cm/Lobulated cortex variable sickness/Adjacent tubal larger node of 2.8 8 1.4 8 1.6 cm./Grossly enlarged nodes; This spontaneous case was reported by a nurse and describes the occurrence of LYMPHADENOPATHY (Axillary Right: Multiple Lymph Node:  3.7 x 2.2 x2.4 cm /lymph node 4.2 x 2.1 x 2.2 cm/Lobulated cortex variable sickness/Adjacent tubal larger node of 2.8 8 1.4 8 1.6 cm./Grossly enlarged nodes) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Quadriplegic infantile cerebral palsy (Since age of 6).   On 21-Feb-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced LYMPHADENOPATHY (Axillary Right: Multiple Lymph Node:  3.7 x 2.2 x2.4 cm /lymph node 4.2 x 2.1 x 2.2 cm/Lobulated cortex variable sickness/Adjacent tubal larger node of 2.8 8 1.4 8 1.6 cm./Grossly enlarged nodes). At the time of the report, LYMPHADENOPATHY (Axillary Right: Multiple Lymph Node:  3.7 x 2.2 x2.4 cm /lymph node 4.2 x 2.1 x 2.2 cm/Lobulated cortex variable sickness/Adjacent tubal larger node of 2.8 8 1.4 8 1.6 cm./Grossly enlarged nodes) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. No treatment medications was reported.  Patient received booster dose on 21-Feb-2022.   Reporter did not allow further contact
Age: 23.0
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, Product storage error
Clinical narrative: Vial was initially stored in the refrigerator on 31-Jan-2022 and administered on 09-Mar-2022; Moderna Covid-19 vaccine that was beyond 30 day use by date was given to 16 patients.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine that was beyond 30 day use by date was given to 16 patients.) and PRODUCT STORAGE ERROR (Vial was initially stored in the refrigerator on 31-Jan-2022 and administered on 09-Mar-2022) in a 23-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042J21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 09-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine that was beyond 30 day use by date was given to 16 patients.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vial was initially stored in the refrigerator on 31-Jan-2022 and administered on 09-Mar-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine that was beyond 30 day use by date was given to 16 patients.) and PRODUCT STORAGE ERROR (Vial was initially stored in the refrigerator on 31-Jan-2022 and administered on 09-Mar-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product information was not provided. The vial was initially stored in the refrigerator on 31-Jan-2022. Treatment information was not provided.   This case was linked to MOD-2022-525860 (Patient Link).
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: woke up today with a horrible shooting pain down her right side that starts at the hip & goes down to the ankle; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (woke up today with a horrible shooting pain down her right side that starts at the hip & goes down to the ankle) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066K21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Mar-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Mar-2022, the patient experienced PAIN (woke up today with a horrible shooting pain down her right side that starts at the hip & goes down to the ankle). At the time of the report, PAIN (woke up today with a horrible shooting pain down her right side that starts at the hip & goes down to the ankle) outcome was unknown.            No concomitant medication was reported. Shooting pain felt down her right side that starts at the hip & went down to the ankle. The same pain was felt after her 2nd dose that lasted about a month & got better after patient went to a walk-in orthopedic clinic and got a steroid injection. No treatment medication was reported.   This case was linked to MOD-2022-525796 (Patient Link).
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Angiocardiogram, Arthralgia, Blood test, COVID-19, Chest pain
Clinical narrative: Severe Covid infection lasting 2 weeks with fever, joint pain, blood clots, severe chest pain, etc. , then following another 2 weeks chest pain, difficulty breathing, dizziness, shortness of breath, joint pain lasting another 2 weeks with severity. Do not feel completely normal yet.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Computerised tomogram thorax, Dizziness, Dyspnoea, Echocardiogram, Electrocardiogram
Clinical narrative: Severe Covid infection lasting 2 weeks with fever, joint pain, blood clots, severe chest pain, etc. , then following another 2 weeks chest pain, difficulty breathing, dizziness, shortness of breath, joint pain lasting another 2 weeks with severity. Do not feel completely normal yet.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Magnetic resonance imaging head, Pyrexia, Thrombosis
Clinical narrative: Severe Covid infection lasting 2 weeks with fever, joint pain, blood clots, severe chest pain, etc. , then following another 2 weeks chest pain, difficulty breathing, dizziness, shortness of breath, joint pain lasting another 2 weeks with severity. Do not feel completely normal yet.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Epistaxis, Paranasal sinus discomfort, Rhinorrhoea, Sinus pain
Clinical narrative: This ?event? occurred  4 months after receiving my booster.  I experienced runny nose, sinus pressure, frequent colorful nasal discharge including blood mucus.  I sinus pain and pressure.  Symptoms lasted a little over three weeks starting on February 6, 2022.  I participated in an exchange of emails (what calls an ?E-Visist? that resulted in a prescription for an antibiotic.  At the end of the  5 day course of antibiotics, my symptoms cleared up.
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: covid vaccine breakthrough case
Age: 61.0
Sex: F
Vaccine: VARZOS
Symptoms: Chills, Feeling cold, Headache, Peripheral coldness, Tremor
Clinical narrative: Intermittent headache especially at right temple, shivering including torso/teeth/hands/arms, body feeling very cold (especially hands and feet) despite multiple layers of clothing and blankets, body temperature at 10:00pm was 97.3 (low for me). Feeling a bit cold began about 5:00pm and continued/worsened for about 6 hours when I fell asleep; was most significant with shaking for about 1 hour+ from 10-11:00pm. I fell asleep with someone closely monitoring me. I woke at 2:30am and removed a second pair of pajamas and socks, and a pair of socks I wore on my hands.  Started feeling better.  Stayed in bed much of the following day.  Feel well now.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Bradycardia, COVID-19, Chest X-ray normal, Computerised tomogram head normal
Clinical narrative: Pt was brought to the ER from nursing facility due to increased weakness for 2 days.   Patient was also reportedly diagnosed with pneumonia at hospital and was started on Levaquin.   In the ER his vitals were stable.  Workup showed unremarkable CBC and CMP except for pancytopenia, COVID-19 PCR came back positive.  Chest x-ray did not show any focal infiltrates.  CT head unremarkable, UA negative.   Patient was started on decadron and  gentle IV fluids and was admitted to hospitalist service. He remained on 4-6 L home oxygen.    Had reach call on 1/11 due to acute change in mental status, bradycardia and concern for aspiration.  He was switched to NPO, repeat CT was unremarkable.  Was started on empiric IV Zosyn.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Computerised tomogram normal, Full blood count normal, Mental status changes, Metabolic function test, Metabolic function test normal
Clinical narrative: Pt was brought to the ER from nursing facility due to increased weakness for 2 days.   Patient was also reportedly diagnosed with pneumonia at hospital and was started on Levaquin.   In the ER his vitals were stable.  Workup showed unremarkable CBC and CMP except for pancytopenia, COVID-19 PCR came back positive.  Chest x-ray did not show any focal infiltrates.  CT head unremarkable, UA negative.   Patient was started on decadron and  gentle IV fluids and was admitted to hospitalist service. He remained on 4-6 L home oxygen.    Had reach call on 1/11 due to acute change in mental status, bradycardia and concern for aspiration.  He was switched to NPO, repeat CT was unremarkable.  Was started on empiric IV Zosyn.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Nothing by mouth order, Pancytopenia, Pneumonia, SARS-CoV-2 test positive, Urine analysis normal
Clinical narrative: Pt was brought to the ER from nursing facility due to increased weakness for 2 days.   Patient was also reportedly diagnosed with pneumonia at hospital and was started on Levaquin.   In the ER his vitals were stable.  Workup showed unremarkable CBC and CMP except for pancytopenia, COVID-19 PCR came back positive.  Chest x-ray did not show any focal infiltrates.  CT head unremarkable, UA negative.   Patient was started on decadron and  gentle IV fluids and was admitted to hospitalist service. He remained on 4-6 L home oxygen.    Had reach call on 1/11 due to acute change in mental status, bradycardia and concern for aspiration.  He was switched to NPO, repeat CT was unremarkable.  Was started on empiric IV Zosyn.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: Poor quality product administered
Clinical narrative: Unviable vaccine given.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Product quality issue
Clinical narrative: unviable vaccine given
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Disturbance in attention, Impaired work ability, Insomnia, Sleep disorder, Tinnitus
Clinical narrative: I woke up in the middle of the night with very loud ringing in both ears the night that I got the booster shot.  I have never had ringing in my ears before.  I continue to have ringing in my ears months later that interfere with ability to sleep and concentrate at work.  The ringing is constant but at time it bursts to very loud noise.
Age: 20.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Abdominal pain upper, COVID-19, Chills, Cholecystitis acute, Computerised tomogram abdomen abnormal
Clinical narrative: Covid19 breakthrough.  1st vaccine received on 05/22/2021.  20 y/o male with PMHX of perforated appendicitis s/p open appy in 2017 with small bowel obstruction s/p exp lap and adhesiolysis in 2017.  Pt presents with c/o Right upper quadrant abdominal/ epigastric pain that is worsening since the day before.  Pt endorses 12 episodes of emesis, chills and constipation.  Pt afebrile, GB US shows acute cholecystitis and possible stone in CBD.  CT abdomen with Small bowel obstruction.  Pt scheduled for colonoscopy/flexible sigmoidoscopy, pre procedure COVID test -positive.  Pt afebrile, room air sat 100%. No Covid treatment ordered.
Age: 20.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Constipation, SARS-CoV-2 test positive, Small intestinal obstruction, Ultrasound biliary tract, Vaccine breakthrough infection
Clinical narrative: Covid19 breakthrough.  1st vaccine received on 05/22/2021.  20 y/o male with PMHX of perforated appendicitis s/p open appy in 2017 with small bowel obstruction s/p exp lap and adhesiolysis in 2017.  Pt presents with c/o Right upper quadrant abdominal/ epigastric pain that is worsening since the day before.  Pt endorses 12 episodes of emesis, chills and constipation.  Pt afebrile, GB US shows acute cholecystitis and possible stone in CBD.  CT abdomen with Small bowel obstruction.  Pt scheduled for colonoscopy/flexible sigmoidoscopy, pre procedure COVID test -positive.  Pt afebrile, room air sat 100%. No Covid treatment ordered.
Age: 20.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Vomiting
Clinical narrative: Covid19 breakthrough.  1st vaccine received on 05/22/2021.  20 y/o male with PMHX of perforated appendicitis s/p open appy in 2017 with small bowel obstruction s/p exp lap and adhesiolysis in 2017.  Pt presents with c/o Right upper quadrant abdominal/ epigastric pain that is worsening since the day before.  Pt endorses 12 episodes of emesis, chills and constipation.  Pt afebrile, GB US shows acute cholecystitis and possible stone in CBD.  CT abdomen with Small bowel obstruction.  Pt scheduled for colonoscopy/flexible sigmoidoscopy, pre procedure COVID test -positive.  Pt afebrile, room air sat 100%. No Covid treatment ordered.
Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Product quality issue
Clinical narrative: unviable vaccine given
Age: 20.0
Sex: F
Vaccine: MENB
Symptoms: Injection site erythema, Injection site swelling, Rash papular
Clinical narrative: Redness and swelling at the injection site. Patient stated that it looked like a red, raised rash.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Product quality issue
Clinical narrative: unviable vaccine given
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Angiogram pulmonary normal, Atelectasis, Azotaemia, Blood bicarbonate abnormal
Clinical narrative: Patient is a 74-year-old female with history of hypertension, CAD, HFpEF, COPD on 5 L home oxygen, diabetes who presented to the ER after a fall at home.  Patient reported to have profuse foul-smelling diarrhea previous to this.  In the ER patient was desatting requiring 6 L nasal cannula which worsened to requiring high-flow nasal cannula. CXR showed mild patchy atelectasis superimposed upon chronic pulmonary fibrosis. Patient found to be COVID-19 positive and was admitted for acute hypoxic respiratory failure requiring BiPAP. Pulm and ID on consult. Pt having worsening azotemia with hypernatremia and hyperkalemia and poor oral intake, Nephrology consulted. Continues to be hypernatremic on freewater and D5W. Code status changed to DNAR after speaking to daughter.  patient requiring high-flow nasal cannula with taking breaks on BiPAP.  Patient's hypoxia advanced and requiring nearly persistent BiPAP.  Pulmonology and Infectious Disease were consulted.  Patient's Decadron was increased to 6 mg b.i.d. And Baricitinib was initiated by Infectious Disease.  Patient was already on Remdesivir.  Patient had some CO2 retention on ABG, after 48 hr patient's bicarb continue to worsen so ABG is being repeated.  Patient has poor oral intake and sodium increased to 156 placed on D5W with good effect.  Nasogastric tube was placed and patient was started on tube feeds.  Patient on persistent BiPAP with oxygen requirements improving.  Patient still having trouble transitioning to high-flow nasal cannula.  On January 24th patient did vomit with BiPAP it was removed very quickly patient is alert.  Patient was initiated on cefepime and Flagyl as prophylaxis for aspiration pneumonia.  NG tube was placed to suction, D-dimer returned greater than 15,000. CT angio of the chest negative for PE.  Patient started to improve but improvement was only for about 2 hr on high-flow than patient was back on BiPAP.  The following day family elected for hospice care.  Patient's NG tube was transitioned back to tube feeds but then discontinued in anticipation of discharge home on hospice.  Patient will be discharged on BiPAP and BiPAP were removed in the home.  Patient is being discharged home on January 28, 2022 in grave condition.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Blood gases abnormal, Blood sodium increased, COVID-19, Chest X-ray abnormal, Diarrhoea
Clinical narrative: Patient is a 74-year-old female with history of hypertension, CAD, HFpEF, COPD on 5 L home oxygen, diabetes who presented to the ER after a fall at home.  Patient reported to have profuse foul-smelling diarrhea previous to this.  In the ER patient was desatting requiring 6 L nasal cannula which worsened to requiring high-flow nasal cannula. CXR showed mild patchy atelectasis superimposed upon chronic pulmonary fibrosis. Patient found to be COVID-19 positive and was admitted for acute hypoxic respiratory failure requiring BiPAP. Pulm and ID on consult. Pt having worsening azotemia with hypernatremia and hyperkalemia and poor oral intake, Nephrology consulted. Continues to be hypernatremic on freewater and D5W. Code status changed to DNAR after speaking to daughter.  patient requiring high-flow nasal cannula with taking breaks on BiPAP.  Patient's hypoxia advanced and requiring nearly persistent BiPAP.  Pulmonology and Infectious Disease were consulted.  Patient's Decadron was increased to 6 mg b.i.d. And Baricitinib was initiated by Infectious Disease.  Patient was already on Remdesivir.  Patient had some CO2 retention on ABG, after 48 hr patient's bicarb continue to worsen so ABG is being repeated.  Patient has poor oral intake and sodium increased to 156 placed on D5W with good effect.  Nasogastric tube was placed and patient was started on tube feeds.  Patient on persistent BiPAP with oxygen requirements improving.  Patient still having trouble transitioning to high-flow nasal cannula.  On January 24th patient did vomit with BiPAP it was removed very quickly patient is alert.  Patient was initiated on cefepime and Flagyl as prophylaxis for aspiration pneumonia.  NG tube was placed to suction, D-dimer returned greater than 15,000. CT angio of the chest negative for PE.  Patient started to improve but improvement was only for about 2 hr on high-flow than patient was back on BiPAP.  The following day family elected for hospice care.  Patient's NG tube was transitioned back to tube feeds but then discontinued in anticipation of discharge home on hospice.  Patient will be discharged on BiPAP and BiPAP were removed in the home.  Patient is being discharged home on January 28, 2022 in grave condition.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Enteral nutrition, Fall, Fibrin D dimer increased, Gastrointestinal tube insertion, General physical health deterioration
Clinical narrative: Patient is a 74-year-old female with history of hypertension, CAD, HFpEF, COPD on 5 L home oxygen, diabetes who presented to the ER after a fall at home.  Patient reported to have profuse foul-smelling diarrhea previous to this.  In the ER patient was desatting requiring 6 L nasal cannula which worsened to requiring high-flow nasal cannula. CXR showed mild patchy atelectasis superimposed upon chronic pulmonary fibrosis. Patient found to be COVID-19 positive and was admitted for acute hypoxic respiratory failure requiring BiPAP. Pulm and ID on consult. Pt having worsening azotemia with hypernatremia and hyperkalemia and poor oral intake, Nephrology consulted. Continues to be hypernatremic on freewater and D5W. Code status changed to DNAR after speaking to daughter.  patient requiring high-flow nasal cannula with taking breaks on BiPAP.  Patient's hypoxia advanced and requiring nearly persistent BiPAP.  Pulmonology and Infectious Disease were consulted.  Patient's Decadron was increased to 6 mg b.i.d. And Baricitinib was initiated by Infectious Disease.  Patient was already on Remdesivir.  Patient had some CO2 retention on ABG, after 48 hr patient's bicarb continue to worsen so ABG is being repeated.  Patient has poor oral intake and sodium increased to 156 placed on D5W with good effect.  Nasogastric tube was placed and patient was started on tube feeds.  Patient on persistent BiPAP with oxygen requirements improving.  Patient still having trouble transitioning to high-flow nasal cannula.  On January 24th patient did vomit with BiPAP it was removed very quickly patient is alert.  Patient was initiated on cefepime and Flagyl as prophylaxis for aspiration pneumonia.  NG tube was placed to suction, D-dimer returned greater than 15,000. CT angio of the chest negative for PE.  Patient started to improve but improvement was only for about 2 hr on high-flow than patient was back on BiPAP.  The following day family elected for hospice care.  Patient's NG tube was transitioned back to tube feeds but then discontinued in anticipation of discharge home on hospice.  Patient will be discharged on BiPAP and BiPAP were removed in the home.  Patient is being discharged home on January 28, 2022 in grave condition.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Hypercapnia, Hyperkalaemia, Hypernatraemia, Hypophagia, Hypoxia
Clinical narrative: Patient is a 74-year-old female with history of hypertension, CAD, HFpEF, COPD on 5 L home oxygen, diabetes who presented to the ER after a fall at home.  Patient reported to have profuse foul-smelling diarrhea previous to this.  In the ER patient was desatting requiring 6 L nasal cannula which worsened to requiring high-flow nasal cannula. CXR showed mild patchy atelectasis superimposed upon chronic pulmonary fibrosis. Patient found to be COVID-19 positive and was admitted for acute hypoxic respiratory failure requiring BiPAP. Pulm and ID on consult. Pt having worsening azotemia with hypernatremia and hyperkalemia and poor oral intake, Nephrology consulted. Continues to be hypernatremic on freewater and D5W. Code status changed to DNAR after speaking to daughter.  patient requiring high-flow nasal cannula with taking breaks on BiPAP.  Patient's hypoxia advanced and requiring nearly persistent BiPAP.  Pulmonology and Infectious Disease were consulted.  Patient's Decadron was increased to 6 mg b.i.d. And Baricitinib was initiated by Infectious Disease.  Patient was already on Remdesivir.  Patient had some CO2 retention on ABG, after 48 hr patient's bicarb continue to worsen so ABG is being repeated.  Patient has poor oral intake and sodium increased to 156 placed on D5W with good effect.  Nasogastric tube was placed and patient was started on tube feeds.  Patient on persistent BiPAP with oxygen requirements improving.  Patient still having trouble transitioning to high-flow nasal cannula.  On January 24th patient did vomit with BiPAP it was removed very quickly patient is alert.  Patient was initiated on cefepime and Flagyl as prophylaxis for aspiration pneumonia.  NG tube was placed to suction, D-dimer returned greater than 15,000. CT angio of the chest negative for PE.  Patient started to improve but improvement was only for about 2 hr on high-flow than patient was back on BiPAP.  The following day family elected for hospice care.  Patient's NG tube was transitioned back to tube feeds but then discontinued in anticipation of discharge home on hospice.  Patient will be discharged on BiPAP and BiPAP were removed in the home.  Patient is being discharged home on January 28, 2022 in grave condition.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Oxygen saturation decreased, Pneumonia aspiration, Positive airway pressure therapy, Pulmonary fibrosis, SARS-CoV-2 test positive
Clinical narrative: Patient is a 74-year-old female with history of hypertension, CAD, HFpEF, COPD on 5 L home oxygen, diabetes who presented to the ER after a fall at home.  Patient reported to have profuse foul-smelling diarrhea previous to this.  In the ER patient was desatting requiring 6 L nasal cannula which worsened to requiring high-flow nasal cannula. CXR showed mild patchy atelectasis superimposed upon chronic pulmonary fibrosis. Patient found to be COVID-19 positive and was admitted for acute hypoxic respiratory failure requiring BiPAP. Pulm and ID on consult. Pt having worsening azotemia with hypernatremia and hyperkalemia and poor oral intake, Nephrology consulted. Continues to be hypernatremic on freewater and D5W. Code status changed to DNAR after speaking to daughter.  patient requiring high-flow nasal cannula with taking breaks on BiPAP.  Patient's hypoxia advanced and requiring nearly persistent BiPAP.  Pulmonology and Infectious Disease were consulted.  Patient's Decadron was increased to 6 mg b.i.d. And Baricitinib was initiated by Infectious Disease.  Patient was already on Remdesivir.  Patient had some CO2 retention on ABG, after 48 hr patient's bicarb continue to worsen so ABG is being repeated.  Patient has poor oral intake and sodium increased to 156 placed on D5W with good effect.  Nasogastric tube was placed and patient was started on tube feeds.  Patient on persistent BiPAP with oxygen requirements improving.  Patient still having trouble transitioning to high-flow nasal cannula.  On January 24th patient did vomit with BiPAP it was removed very quickly patient is alert.  Patient was initiated on cefepime and Flagyl as prophylaxis for aspiration pneumonia.  NG tube was placed to suction, D-dimer returned greater than 15,000. CT angio of the chest negative for PE.  Patient started to improve but improvement was only for about 2 hr on high-flow than patient was back on BiPAP.  The following day family elected for hospice care.  Patient's NG tube was transitioned back to tube feeds but then discontinued in anticipation of discharge home on hospice.  Patient will be discharged on BiPAP and BiPAP were removed in the home.  Patient is being discharged home on January 28, 2022 in grave condition.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Patient is a 74-year-old female with history of hypertension, CAD, HFpEF, COPD on 5 L home oxygen, diabetes who presented to the ER after a fall at home.  Patient reported to have profuse foul-smelling diarrhea previous to this.  In the ER patient was desatting requiring 6 L nasal cannula which worsened to requiring high-flow nasal cannula. CXR showed mild patchy atelectasis superimposed upon chronic pulmonary fibrosis. Patient found to be COVID-19 positive and was admitted for acute hypoxic respiratory failure requiring BiPAP. Pulm and ID on consult. Pt having worsening azotemia with hypernatremia and hyperkalemia and poor oral intake, Nephrology consulted. Continues to be hypernatremic on freewater and D5W. Code status changed to DNAR after speaking to daughter.  patient requiring high-flow nasal cannula with taking breaks on BiPAP.  Patient's hypoxia advanced and requiring nearly persistent BiPAP.  Pulmonology and Infectious Disease were consulted.  Patient's Decadron was increased to 6 mg b.i.d. And Baricitinib was initiated by Infectious Disease.  Patient was already on Remdesivir.  Patient had some CO2 retention on ABG, after 48 hr patient's bicarb continue to worsen so ABG is being repeated.  Patient has poor oral intake and sodium increased to 156 placed on D5W with good effect.  Nasogastric tube was placed and patient was started on tube feeds.  Patient on persistent BiPAP with oxygen requirements improving.  Patient still having trouble transitioning to high-flow nasal cannula.  On January 24th patient did vomit with BiPAP it was removed very quickly patient is alert.  Patient was initiated on cefepime and Flagyl as prophylaxis for aspiration pneumonia.  NG tube was placed to suction, D-dimer returned greater than 15,000. CT angio of the chest negative for PE.  Patient started to improve but improvement was only for about 2 hr on high-flow than patient was back on BiPAP.  The following day family elected for hospice care.  Patient's NG tube was transitioned back to tube feeds but then discontinued in anticipation of discharge home on hospice.  Patient will be discharged on BiPAP and BiPAP were removed in the home.  Patient is being discharged home on January 28, 2022 in grave condition.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Ataxia, Blood magnesium, Blood phosphorus, C-reactive protein, Electrocardiogram
Clinical narrative: Mental fogginess, ataxia, lower extremity tremors, ocular migraines.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Feeling abnormal, Full blood count, Metabolic function test, Ophthalmic migraine, Red blood cell sedimentation rate
Clinical narrative: Mental fogginess, ataxia, lower extremity tremors, ocular migraines.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Tremor, Vitamin D
Clinical narrative: Mental fogginess, ataxia, lower extremity tremors, ocular migraines.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Dyspnoea, Throat irritation
Clinical narrative: Patient called health department on 3/29/22 to let us know about reaction she developed 25 hours after her booster shot. She notified her allergist Dr. At her December visit about it, and he told her to let us know that maybe it could have been a reaction but he was unsure. she did not call us until 3/29/22 to report. She stated that on 9/22 around 5pm she felt a tickle in her throat that caused SOB and coughing episodes couldn't catch her breath, she felt the tickle for about an hour. Immediately she took benadryl  and within in an hour it went away. She did not have any issues with first 2 vaccines.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Moderna 6/11/21, 7/9/21, 1/21/22. Positive on 3/29
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test normal, Psoriasis, Skin atrophy, Skin discolouration
Clinical narrative: 05/08/2021 I Noticed while working outside, if I bumped my arm, these huge purple spots would come up. My skin would tear very easily, my skin was very thin. Went to my family doctor, he looked at my medications. Said there is nothing on there that would cause this. I went to my dermatologist. He looked at my medications and said, no, unfortunately, I think it is because you are getting older. Then I noticed, I have had Plaque psoriasis it has been contained to my scalp. Still to this day, I worked outside two weeks ago, and just bumping my skin, I have purple spots on my forearm and tops of my hands.
Age: 23.0
Sex: M
Vaccine: COVID19
Symptoms: Biopsy skin abnormal, Guttate psoriasis
Clinical narrative: Severe outbreak of psoriasis
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Discomfort, Feeling abnormal, Impaired work ability, Lymph node pain, Lymphadenopathy
Clinical narrative: After I received me second vaccine, I woke up overnight with a fever of 102 I think it was, I took some Tylenol to help with that so I could sleep. Then my lymph nodes at the base of my neck where it meets my shoulder swelled up on both sides, but more significantly in my left side where I got the vaccine. It was painful to the touch. I called my doctor and she had me come in. She said it was a potential side effect of the vaccine but it was on the extreme side of it. She advised me to continue taking Tylenol or Advil, which I did do. And if the swelling was bad to use warm compresses. And if the swelling didn't go down in within 2 weeks to follow up with her. It went away in about a week roughly. I ended up missing 2 days of work when I had the fever. I had to wait for it to go down because that was the policy where I work at and also I was so uncomfortable and felt miserable.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: After I received me second vaccine, I woke up overnight with a fever of 102 I think it was, I took some Tylenol to help with that so I could sleep. Then my lymph nodes at the base of my neck where it meets my shoulder swelled up on both sides, but more significantly in my left side where I got the vaccine. It was painful to the touch. I called my doctor and she had me come in. She said it was a potential side effect of the vaccine but it was on the extreme side of it. She advised me to continue taking Tylenol or Advil, which I did do. And if the swelling was bad to use warm compresses. And if the swelling didn't go down in within 2 weeks to follow up with her. It went away in about a week roughly. I ended up missing 2 days of work when I had the fever. I had to wait for it to go down because that was the policy where I work at and also I was so uncomfortable and felt miserable.
Age: 55.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Tinnitus
Clinical narrative: Continuous ringing in both ears. Sounds like the electrical noise from the back of an old tube type television. High pitched hum/ring that I would guess everyone has experienced from time to time, but this one never goes away. If in a noisy area, the ringing is not apparent. If in a relatively quiet area, the ringing is forefront and quite annoying. I don't recall the exact date that I realized it was ringing that wasn't going away, but I believe it was sometime in February 2022 - This is when I first mentioned it to my wife.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: unviable vaccine given
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: unviable vaccine given
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Headache, Injection site pain, Pain, Pyrexia
Clinical narrative: 3/30/2022 at 0747 Employee notified the Nurse Vaccine Support line to report symptoms post COVID-19 booster vaccine. Vaccine Name - Pfizer Vaccine Date - 3/28/2022 Booster Dose - Yes Location - Right Deltoid Date of Symptom Onset - 3/28/2022 (Night of ) Symptoms - Fever (Tmax 102F), Headache, Left Axilla Pain, Tenderness at Injection Site, Body Aches (Last Fever on 3/29/22) Last Day of Work and Shift - 3/28/2022 (Regular shift Days) Home Remedies - Ibuprofen 600 mg twice, Warm compress (Unable to do cold due to comorbid - Sickle Cell) Any Improvement - Yes (Fever subsided), however, R arm tenderness remains
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Tenderness
Clinical narrative: 3/30/2022 at 0747 Employee notified the Nurse Vaccine Support line to report symptoms post COVID-19 booster vaccine. Vaccine Name - Pfizer Vaccine Date - 3/28/2022 Booster Dose - Yes Location - Right Deltoid Date of Symptom Onset - 3/28/2022 (Night of ) Symptoms - Fever (Tmax 102F), Headache, Left Axilla Pain, Tenderness at Injection Site, Body Aches (Last Fever on 3/29/22) Last Day of Work and Shift - 3/28/2022 (Regular shift Days) Home Remedies - Ibuprofen 600 mg twice, Warm compress (Unable to do cold due to comorbid - Sickle Cell) Any Improvement - Yes (Fever subsided), however, R arm tenderness remains
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Psoriasis
Clinical narrative: 11/21/2021. I noticed my skin started itching and I had psoriasis come up out of the blue. No stress related issues. Went back to dermatologist last month, and he looked at the new psoriasis on my body. He had prescribed medication to use on my head. The treatment plan was to use medication on my body every day, if that doesn't work, we would try the injectable. Psoriasis covers 20% of my body.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, COVID-19, Condition aggravated, Cough
Clinical narrative: For each shot same side effects. Arm sore 2 days muscles aches 36 hours. However, February 24, 2022 afebrile but got raspy throat which advanced into cough, congestion mild headache and tiredness over 2 days. 2/26 at home tested negative for COVID. Tuesday 2/28 loss of taste and smell re-tested and positive for COVID. Improvement started 3/1. 3/3 congestion improved, still headache and tiredness. 3/6 re-tested positive for COVID (5 days post 1st symptoms. 3/7 contacted Dr. and told to continue isolation for total of 10 days post 1st positive test i.e. through 3/10. Retested on 3/10 negative for COVID (confirmed with 2 different manufacturers home test).
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Dysphonia, Fatigue, Headache, Myalgia, Pain in extremity
Clinical narrative: For each shot same side effects. Arm sore 2 days muscles aches 36 hours. However, February 24, 2022 afebrile but got raspy throat which advanced into cough, congestion mild headache and tiredness over 2 days. 2/26 at home tested negative for COVID. Tuesday 2/28 loss of taste and smell re-tested and positive for COVID. Improvement started 3/1. 3/3 congestion improved, still headache and tiredness. 3/6 re-tested positive for COVID (5 days post 1st symptoms. 3/7 contacted Dr. and told to continue isolation for total of 10 days post 1st positive test i.e. through 3/10. Retested on 3/10 negative for COVID (confirmed with 2 different manufacturers home test).
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Quarantine, Respiratory tract congestion, SARS-CoV-2 test negative, SARS-CoV-2 test positive
Clinical narrative: For each shot same side effects. Arm sore 2 days muscles aches 36 hours. However, February 24, 2022 afebrile but got raspy throat which advanced into cough, congestion mild headache and tiredness over 2 days. 2/26 at home tested negative for COVID. Tuesday 2/28 loss of taste and smell re-tested and positive for COVID. Improvement started 3/1. 3/3 congestion improved, still headache and tiredness. 3/6 re-tested positive for COVID (5 days post 1st symptoms. 3/7 contacted Dr. and told to continue isolation for total of 10 days post 1st positive test i.e. through 3/10. Retested on 3/10 negative for COVID (confirmed with 2 different manufacturers home test).
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Mobility decreased, Pain, Peripheral swelling
Clinical narrative: The day after the shot I had shallowing of my arm and red spot. Loss of motion in my upper left arm. Constant soreness.